IGC PharmaIGC +1.83%29 Pretax Margin % is -757.73% as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 946 Biotechnology companies, IGC Pharma ranks worse than 71.56% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. IGC Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-2.40 Mil. IGC Pharma's Revenue for the
three
months ended in Mar. 2026 was $0.32 Mil. Therefore, IGC Pharma's pretax margin for the quarter that ended in Mar. 2026 was -757.73%.
The historical rank and industry rank for IGC Pharma's Pretax Margin % or its related term are showing as below:
IGC'
s Pretax Margin % Range Over the Past 10 Years
Min: -3782.37 Med: -438.59 Max: -44.5
Current: -552.11
IGC's Pretax Margin % is ranked worse than 71.56% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs IGC: -552.11
IGC Pharma (AMEX:IGC) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
IGC Pharma Pretax Margin % Related Terms
IGC Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for IGC Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC vs CRVO, NEUP, CELU: Pretax Margin % Comparison
For the Biotechnology subindustry, IGC Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a Pretax Margin % of -757.73% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #677 out of 946 companies in the Biotechnology industry, placing it in the top 71.6%.
Is IGC Pharma's Pretax Margin % too high?
IGC Pharma's current Pretax Margin % is -757.73%. Based on the distribution chart, IGC Pharma ranks #677 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Pretax Margin % compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #677 out of 946 companies for Pretax Margin %. This places IGC Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on IGC Pharma and its competitors. IGC Pharma's current Pretax Margin % is -757.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 11.1% above its estimated fair value. The current Pretax Margin % is -757.73%. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For IGC Pharma (IGC), the current Pretax Margin % is -757.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.27 is trading 11.1% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Modestly Overvalued.
Key valuation signals for IGC:
Pretax Margin %: -757.73%
GF Value™: $0.24 vs. price of $0.27 (11.1% above fair value)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
